Moonlight Therapeutics is a pre-clinical stage biotech company dedicated to developing a groundbreaking treatment for individuals with food allergies. With a focus on peanut allergy, Moonlight is currently developing its first therapy, MOON101, which utilizes its proprietary skin stamp technology. The company's founders are experts in drug delivery and have designed a system that effectively delivers drugs to their intended targets by overcoming the body's barriers.

By breaking through the skin barrier and delivering antigen to the skin's immune cells, Moonlight aims to protect patients from dangerous anaphylactic reactions. The company has received significant funding from the National Institutes of Health for the development of this platform and MOON101. Moonlight's dedicated team, with extensive experience in research, early-stage drug development, and leadership roles in the biotechnology industry, is driven to advance the treatment for peanut allergies.

Led by President and CEO Samir Patel, along with COO Vladimir Zarnitsyn, Moonlight Therapeutics is on a mission to improve the lives of those affected by food allergies